Research Topics
| Loren K MellSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Reporting of cause-specific treatment effects in cancer clinical trials with competing risks: a systematic reviewLoren K Mell
Department of Radiation Oncology, University of California San Diego, La Jolla, CA, USA
Contemp Clin Trials 33:920-4. 2012..We sought to determine the extent to which cause-specific effects on primary events are reported in contemporary randomized controlled trials in oncology...
A comparison of dose-response characteristics of four NTCP models using outcomes of radiation-induced optic neuropathy and retinopathyVitali Moiseenko
University of Florida Health Sciences Center, Gainesville, FL 32610 0385, USA
Radiat Oncol 6:61. 2011..In particular, the question to what extent model predictions are data-driven or dependent on the choice of the model has to be explored...- Predictors of competing mortality in advanced head and neck cancerLoren K Mell
University of California San Diego, Moores Cancer Center, Department of Radiation Oncology, 3855 Health Sciences Dr MC 0843, La Jolla, CA 92129, USA
J Clin Oncol 28:15-20. 2010..Analyses of risk factors for competing mortality may be useful in outcomes reporting and designing clinical trials... - Predictors of competing mortality in early breast cancerLoren K Mell
Department of Radiation Oncology, University of California San Diego Moores Cancer Center, La Jolla, California 92129, USA
Cancer 116:5365-73. 2010..Death in the absence of disease recurrence (competing mortality) is an important determinant of disease-free survival (DFS) in early breast cancer. The authors sought to identify predictors of this event using competing risks modeling... - Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapyBrent S Rose
Department of Radiation Oncology and Center for Advanced Radiotherapy Technologies, University of California, San Diego, La Jolla, CA 92093 0843, USA
Int J Radiat Oncol Biol Phys 79:800-7. 2011.... - Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapyBrent S Rose
Department of Radiation Oncology and Center for Advanced Radiotherapy Technologies, Rebecca and John Moores Comprehensive Cancer Center, University of California, San Diego, La Jolla, CA, USA
Int J Radiat Oncol Biol Phys 83:1185-91. 2012.... - Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignanciesYun Liang
Department of Radiation Oncology, and Center for Advanced Radiotherapy Technologies, University of California, San Diego, La Jolla, California 92093, USA
Int J Radiat Oncol Biol Phys 85:406-14. 2013.... - Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatinDaniel R Simpson
Center for Advanced Radiotherapy Technologies, Department of Radiation Oncology, University of California San Diego, La Jolla, CA, USA
Int J Radiat Oncol Biol Phys 83:e81-6. 2012.... - A survey of image-guided radiation therapy use in the United StatesDaniel R Simpson
Department of Radiation Oncology, Center for Advanced Radiotherapy Technologies, University of California San Diego, La Jolla, California 92093 0843, USA
Cancer 116:3953-60. 2010..Image-guided radiation therapy (IGRT) is a novel array of in-room imaging modalities that are used for tumor localization and patient setup in radiation oncology. The prevalence of IGRT use among US radiation oncologists is unknown... - Optimized planning target volume for intact cervical cancerAlvin Khan
Department of Radiation Oncology, Center for Advanced Radiotherapy Technologies, University of California, San Diego, La Jolla, CA, USA
Int J Radiat Oncol Biol Phys 83:1500-5. 2012..To model interfraction clinical target volume (CTV) variation in patients with intact cervical cancer and design a planning target volume (PTV) that minimizes normal tissue dose while maximizing CTV coverage... - Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatinLindsay G Jensen
Department of Radiation Oncology, University of California San Diego, La Jolla, CA 92093, USA
Int J Gynecol Cancer 23:119-25. 2013..To evaluate disease outcomes and toxicity in patients with cervical cancer treated with extended-field intensity-modulated radiotherapy... - Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional dataYun Liang
Department of Radiation Oncology, Center for Advanced Radiotherapy Technologies, University of California San Diego, La Jolla, California, USA
Int J Radiat Oncol Biol Phys 78:912-9. 2010..To study the effects of increasing pelvic bone marrow (BM) radiation dose on acute hematologic toxicity in patients undergoing chemoradiotherapy, using a novel modeling approach to preserve the local spatial dose information... - Population-based study of competing mortality in head and neck cancerBrent S Rose
Department of Radiation Oncology, 3855 Health Sciences Dr, MC0843, La Jolla, CA 92093, USA
J Clin Oncol 29:3503-9. 2011..Variation in competing mortality risk complicates individual treatment choices and design and interpretation of clinical studies... - A survey of stereotactic body radiotherapy use in the United StatesHubert Pan
Department of Radiation Oncology, Center for Advanced Radiotherapy Technologies, University of California at San Diego, La Jolla, California, USA
Cancer 117:4566-72. 2011..To the authors' knowledge, the prevalence of SBRT use among radiation oncologists in the United States is unknown... - Daily online cone beam computed tomography to assess interfractional motion in patients with intact cervical cancerNeelam Tyagi
Department of Radiation Oncology and Center for Advanced Radiotherapy Technologies, University of California San Diego, La Jolla, California 92093 0843, USA
Int J Radiat Oncol Biol Phys 80:273-80. 2011..To quantify interfraction motion in patients with intact cervical cancer and assess implications for clinical target volume (CTV) coverage and required planning margins... - Utilization of advanced imaging technologies for target delineation in radiation oncologyDaniel R Simpson
Department of Radiation Oncology and Center for Advanced Radiotherapy Technologies, Rebecca and John Moores Comprehensive Cancer Center, University of California, San Diego, La Jolla, California 92093 0843, USA
J Am Coll Radiol 6:876-83. 2009..The aim of this study was to evaluate the utilization of advanced imaging technologies for target delineation among radiation oncologists in the United States... 
Dosimetric comparison study between intensity modulated radiation therapy and three-dimensional conformal proton therapy for pelvic bone marrow sparing in the treatment of cervical cancerWilliam Y Song
Department of Radiation Oncology, University of California San Diego, La Jolla, CA, USA
J Appl Clin Med Phys 11:3255. 2010..Further studies are, however, needed to fully exploit the benefits of protons for general use in cervical cancer...- Liver motion during cone beam computed tomography guided stereotactic body radiation therapyJustin C Park
Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA
Med Phys 39:6431-42. 2012..The purpose of this study was to investigate such motion characteristics based on fiducial markers tracked with the x-ray projections of the CBCT scans, taken immediately prior to the treatments... - Competing event risk stratification may improve the design and efficiency of clinical trials: secondary analysis of SWOG 8794Kaveh Zakeri
Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, United States
Contemp Clin Trials 34:74-9. 2013..Composite endpoints can be problematic in the presence of competing risks when a treatment does not affect events comprising the endpoint equally... - Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostineLoren K Mell
University of California San Diego, Department of Radiation Oncology, La Jolla, California, USA
Expert Opin Drug Metab Toxicol 4:1341-50. 2008..Amifostine is a cytoprotector that can reduce toxicity and potentially improve the therapeutic ratio of radiotherapy...